SCHEDULE 13G/A: Weber Capital Management Discloses 7.26% Stake in Harvard Bioscience Inc.

Weber Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 7.26% of Harvard Bioscience Inc.'s common stock as of March 31, 2025.

Summary

• Weber Capital Management, LLC reported beneficial ownership of 3,200,380 shares of Harvard Bioscience Inc. common stock.
• This represents 7.26% of the total outstanding common stock of Harvard Bioscience Inc.
• The filing indicates that Weber Capital Management, LLC holds shared voting power and shared dispositive power over all 3,200,380 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership, which is inherently neutral in sentiment regarding the issuer's performance or prospects.

Positives

• Weber Capital Management, LLC, an investment adviser, holds a significant stake, indicating potential confidence in Harvard Bioscience Inc.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of Harvard Bioscience Inc., mitigating risks associated with activist investor intervention.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Harvard Bioscience Inc.'s future outlook.

Management Comments

• Colin Hillberg, Manager of Weber Capital Management, LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Industry Context

This filing primarily concerns a change in beneficial ownership by an investment adviser and does not provide specific insights into broader industry trends or competitive landscape for Harvard Bioscience Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which may influence market perception.

Key Dates

Keywords

Harvard Bioscience Inc, Weber Capital Management, Schedule 13G, Common Stock, Beneficial Ownership, Investment Adviser, SEC Filing, Equity Stake